<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: candidates", fill: "#0095b6"},
{source: "2: candidates", target: "2: development", fill: "#0095b6"},
{source: "2: development", target: "2: products under development will", fill: "#0095b6"},
{source: "2: products under development will", target: "2: commercialized", fill: "#0095b6"},
{source: "2: candidates", target: "3: must successfully research", fill: "#635147"},
{source: "3: must successfully research", target: "3: regulatory", fill: "#635147"},
{source: "3: regulatory", target: "3: manufacture introduce market", fill: "#635147"},
{source: "3: manufacture introduce market", target: "3: under development", fill: "#635147"},
{source: "3: must successfully research", target: "9: factors affect", fill: "#2e8b57"},
{source: "9: factors affect", target: "9: enrollment", fill: "#2e8b57"},
{source: "9: enrollment", target: "9: patient population", fill: "#2e8b57"},
{source: "9: patient population", target: "9: clinical sites", fill: "#2e8b57"},
{source: "9: clinical sites", target: "9: eligibility criteria", fill: "#2e8b57"},
{source: "9: eligibility criteria", target: "9: trial competing clinical trials", fill: "#2e8b57"},
{source: "9: trial competing clinical trials", target: "9: procedures used", fill: "#2e8b57"},
{source: "9: procedures used", target: "9: conditions", fill: "#2e8b57"},
{source: "9: conditions", target: "9: investigating", fill: "#2e8b57"},
{source: "9: factors affect", target: "10: conducting clinical", fill: "#40826d"},
{source: "10: conducting clinical", target: "10: future trials", fill: "#40826d"},
{source: "10: future trials", target: "10: seek patients with", fill: "#40826d"},
{source: "10: seek patients with", target: "10: same diseases", fill: "#40826d"},
{source: "10: conducting clinical", target: "11: adequate levels", fill: "#d70040"},
{source: "11: adequate levels", target: "11: patient enrollment", fill: "#d70040"},
{source: "11: patient enrollment", target: "11: clinical trials", fill: "#d70040"},
{source: "11: adequate levels", target: "18: Moreover ", fill: "#808080"},
{source: "18: Moreover ", target: "18: data from clinical trials", fill: "#808080"},
{source: "18: data from clinical trials", target: "18: interpretations", fill: "#808080"},
{source: "18: interpretations", target: "18: could delay limit", fill: "#808080"},
{source: "18: could delay limit", target: "18: prevent regulatory approval", fill: "#808080"},
{source: "18: Moreover ", target: "20: adequately demonstrate", fill: "#abcdef"},
{source: "20: adequately demonstrate", target: "20: effectiveness", fill: "#abcdef"},
{source: "20: effectiveness", target: "20: product under development could limit", fill: "#abcdef"},
{source: "20: product under development could limit", target: "20: regulatory approval", fill: "#abcdef"},
{source: "20: regulatory approval", target: "20: potential product", fill: "#abcdef"},
{source: "20: potential product", target: "20: would materially harm", fill: "#abcdef"},
{source: "20: adequately demonstrate", target: "49: governmental", fill: "#0ff"},
{source: "49: governmental", target: "49: regulations", fill: "#0ff"},
{source: "49: regulations", target: "49: adversely", fill: "#0ff"},
{source: "49: governmental", target: "64: following events", fill: "#f56991"},
{source: "64: following events", target: "64: could delay", fill: "#f56991"},
{source: "64: could delay", target: "64: us from further", fill: "#f56991"},
{source: "64: us from further", target: "64: commercial use", fill: "#f56991"},
{source: "64: commercial use", target: "64: products which", fill: "#f56991"},
{source: "64: products which", target: "64: financial condition", fill: "#f56991"},
{source: "64: financial condition", target: "64: operations", fill: "#f56991"},
{source: "64: operations", target: "64: requisite governmental", fill: "#f56991"},
{source: "64: requisite governmental", target: "64: specific indications", fill: "#f56991"},
{source: "64: specific indications", target: "64: under development", fill: "#f56991"},
{source: "64: under development", target: "64: identification", fill: "#f56991"},
{source: "64: identification", target: "64: unanticipated adverse", fill: "#f56991"},
{source: "64: unanticipated adverse", target: "64: products under development", fill: "#f56991"},
{source: "64: following events", target: "START_HERE", fill: "#f56991"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Offer peace proposal</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Human_development">Human development</a></td>
      <td>The Human Development Index (HDI) is a statistic composite index of life expectancy, education (mean years of schooling completed and expected years of schooling upon entering the education system), and per capita income indicators, which are used to rank countries into four tiers of human development. A country scores a higher level of HDI when the lifespan is higher, the education level is higher, and the gross national income GNI (PPP) per capita is higher.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_agency">Regulatory agency</a></td>
      <td>A regulatory agency (regulatory body, regulator) or independent agency (independent regulatory agency) is a government authority that is responsible for exercising autonomous dominion over some area of human activity in a licensing and regulating capacity.\nThese are customarily set up to strengthen safety and standards, and/or to protect consumers in markets where there is a lack of effective competition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_state">Regulatory state</a></td>
      <td>The term regulatory state refers to the expansion in the use of rulemaking, monitoring and enforcement techniques and institutions by the state and to a parallel change in the way its positive or negative functions in society are being carried out. The expansion of the state nowadays is generally via regulation and less via taxing and spending.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capitalism">Regulatory capitalism</a></td>
      <td>Regulatory capitalism suggests that the operation maintenance and development of the international political economy increasingly depends on administrative rules outside the legislatures and the courts. In other words, it tells us that capitalism is a regulatory institution – one that is being constituted, shaped, constrained and expanded as a historically woven patchwork of regulatory institutions, strategies, and functions.Although this patchwork varies widely across regions, nations, regimes, sectors, issues, and arenas, the general trend despite and beyond the process of liberalization is that of growth rather than decline of the role regulation in shaping policy and politics.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sequence">Regulatory sequence</a></td>
      <td>A regulatory sequence is a segment of a nucleic acid molecule which is capable of increasing or decreasing the expression of specific genes within an organism. Regulation of gene expression is an essential feature of all living organisms and viruses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_affairs">Regulatory affairs</a></td>
      <td>Regulatory affairs (RA), also called government affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, cosmetics, agrochemicals (plant protection products and fertilizers), energy, banking, telecom etc.  Regulatory affairs also has a very specific meaning within the healthcare industries (pharmaceuticals, medical devices, biologics and functional foods).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sign">Regulatory sign</a></td>
      <td>A regulatory sign is used to indicate or reinforce traffic laws, regulations or requirements which apply either at all times or at specified times or places upon a street or highway, the disregard of which may constitute a violation, or a sign in general that regulates public behavior in places open to the public.  The FHWA defines regulatory sign as "a sign that gives notice to road users of traffic laws or regulations".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_T_cell">Regulatory T cell</a></td>
      <td>The regulatory T cells (Tregs  or Treg cells), formerly known as suppressor T cells, are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Treg cells are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cis-regulatory_element">Cis-regulatory element</a></td>
      <td>Cis-regulatory elements (CREs) or Cis-regulatory modules (CRMs) are regions of non-coding DNA which regulate the transcription of neighboring genes. CREs are vital components of genetic regulatory networks, which in turn control morphogenesis, the development of anatomy, and other aspects of embryonic development, studied in evolutionary developmental biology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Controlled_clinical_trials">Controlled clinical trials</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tecovirimat">Tecovirimat</a></td>
      <td>Tecovirimat, sold under the brand name Tpoxx among others, is an antiviral medication with activity against orthopoxviruses such as smallpox and monkeypox. It is the first antipoxviral drug approved in the United States.The drug works by blocking cellular transmission of the virus, thus preventing the disease.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Praziquantel">Praziquantel</a></td>
      <td>Praziquantel (PZQ), sold under the brandname Biltricide among others, is a medication used to treat a number of types of parasitic worm infections in mammals, birds, amphibians, reptiles, and fish. In humans specifically, it is used to treat schistosomiasis, clonorchiasis, opisthorchiasis, tapeworm infections, cysticercosis, hydatid disease, and other fluke infections.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Merger_of_Sprint_Corporation_and_T-Mobile_US">Merger of Sprint Corporation and T-Mobile US</a></td>
      <td>Sprint Corporation and T-Mobile US merged in 2020 in an all shares deal for $26 billion. The deal was announced on April 29, 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Denosumab">Denosumab</a></td>
      <td>Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.Denosumab is contraindicated in people with low blood calcium levels. The most common side effects are joint and muscle pain in the arms or legs.Denosumab is a inhibitor of RANKL (receptor activator of nuclear factor kappa-Β ligand), which works by preventing the development of osteoclasts, which are cells that break down bone.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gilead_Sciences">Gilead Sciences</a></td>
      <td>Gilead Sciences, Inc. , is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_(European_Union)">Regulation (European Union)</a></td>
      <td>A regulation is a legal act of the European Union that becomes immediately enforceable as law in all member states simultaneously. Regulations can be distinguished from directives which, at least in principle, need to be transposed into national law.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>PHARMACYCLICS INC      Item 1A Risk Factors                                       RISK FACTORS          You <font color="blue">should carefully</font> consider these <font color="blue">risk factors as each</font> of these risks     could  <font color="blue">adversely</font>  affect our business, operating results and financial     condition</td>
    </tr>
    <tr>
      <td>Risks Related to Pharmacyclics     All of our product <font color="blue">candidates</font> are in <font color="blue">development</font>, and we cannot be certain         that any of our products under <font color="blue">development</font> will be <font color="blue"><font color="blue">commercialize</font>d</font></td>
    </tr>
    <tr>
      <td>To be profitable, we <font color="blue">must <font color="blue">successfully</font> research</font>, develop, obtain <font color="blue">regulatory</font>     approval for, <font color="blue">manufacture</font>, introduce, market and distribute our products     under <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>The time <font color="blue">frame <font color="blue">necessary</font></font> to achieve these goals for any     individual product is long and uncertain</td>
    </tr>
    <tr>
      <td>Before we can sell any of our     products under <font color="blue">development</font>, we <font color="blue">must <font color="blue">demonstrate</font></font> to the <font color="blue">satisfaction</font> of the     FDA and <font color="blue">regulatory</font> <font color="blue">authorities</font> in foreign markets through the submission of     preclinical (animal) studies and clinical (human) trials that each product     is safe and <font color="blue">effective</font> for human use for each targeted disease</td>
    </tr>
    <tr>
      <td>We have     conducted and plan to continue to conduct extensive and <font color="blue">costly clinical</font>     trials to assess the safety and <font color="blue">effective</font>ness of our <font color="blue"><font color="blue">potential product</font>s</font></td>
    </tr>
    <tr>
      <td>We     cannot be certain that we will be permitted to begin or continue our planned     clinical  trials for our <font color="blue"><font color="blue">potential product</font>s</font>, or if permitted, that our     <font color="blue"><font color="blue">potential product</font>s</font> will prove to be safe and produce their <font color="blue">intended effects</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">completion</font>  rate of our <font color="blue">clinical trials</font> depends upon, among other     factors, the rate of <font color="blue">patient <font color="blue">enrollment</font></font>, the adequacy of patient follow-up     and the <font color="blue">completion</font> of required <font color="blue">clinical evaluations</font></td>
    </tr>
    <tr>
      <td>Many <font color="blue">factors affect</font>     patient  <font color="blue">enrollment</font>, including the size of the <font color="blue">patient population</font>, the     proximity of patients to <font color="blue">clinical sites</font>, the <font color="blue">eligibility criteria</font> for the     trial, competing <font color="blue">clinical trials</font> and new drugs or <font color="blue">procedures used</font> for the     <font color="blue">conditions</font> we are <font color="blue">investigating</font></td>
    </tr>
    <tr>
      <td>Other companies are <font color="blue">conducting clinical</font>     trials and have announced plans for <font color="blue">future trials</font> that are seeking or are     likely to <font color="blue">seek patients with</font> the <font color="blue">same diseases</font> that we are studying</td>
    </tr>
    <tr>
      <td>We may     fail to obtain <font color="blue">adequate levels</font> of <font color="blue">patient <font color="blue">enrollment</font></font> in our <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>Delays in planned <font color="blue">patient <font color="blue">enrollment</font></font> may result in <font color="blue">increased costs</font>, delays     or <font color="blue">termination</font> of <font color="blue">clinical trials</font>, which could have a material adverse     effect on us</td>
    </tr>
    <tr>
      <td>Many factors can affect the adequacy of patient follow-up and     <font color="blue">completion</font> of required <font color="blue">clinical evaluations</font>, including failure of patients     to return for <font color="blue">scheduled visits</font> or failure of <font color="blue">clinical sites</font> to complete     <font color="blue"><font color="blue">necessary</font> <font color="blue">documentation</font></font></td>
    </tr>
    <tr>
      <td>Delays in or failure to obtain required clinical     follow-up and <font color="blue">completion</font> of <font color="blue">clinical evaluations</font> <font color="blue">could also</font> have a material     adverse effect on the timing and outcome of our <font color="blue">clinical trials</font> and product     approvals</td>
    </tr>
    <tr>
      <td>Additionally,  clinical  trials require substantial <font color="blue">administration</font> and     monitoring</td>
    </tr>
    <tr>
      <td>We may fail to <font color="blue">effective</font>ly oversee and monitor the various     trials  we  have <font color="blue">underway at</font> any particular time <font color="blue">which would</font> result in     <font color="blue">increased costs</font> or delays of our <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>Data already obtained <font color="blue">from preclinical studies</font> and <font color="blue">clinical trials</font> of our     products under <font color="blue">development</font> do not <font color="blue">necessarily predict</font> the results that will     be obtained <font color="blue">from later preclinical studies</font> and <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>Moreover,     data from <font color="blue">clinical trials</font> we are conducting are susceptible to varying     <font color="blue"><font color="blue">interpretation</font>s</font> that <font color="blue">could delay</font>, limit or prevent <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>A     number of companies in the <font color="blue"><font color="blue">pharmaceutical</font> industry</font> have <font color="blue">suffered <font color="blue">significant</font></font>     setbacks  in advanced <font color="blue">clinical trials</font>, even after promising results in     earlier  trials</td>
    </tr>
    <tr>
      <td>The failure to <font color="blue"><font color="blue">adequately</font> <font color="blue">demonstrate</font></font> the safety and     <font color="blue">effective</font>ness  of  a  product under <font color="blue">development</font> could limit or prevent     <font color="blue">regulatory</font> approval of the <font color="blue">potential product</font> and <font color="blue">would <font color="blue">materially</font> harm</font> our     business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">clinical trials</font> may not <font color="blue">demonstrate</font> the <font color="blue">sufficient levels</font> of     safety and <font color="blue">efficacy <font color="blue">necessary</font></font> to obtain the requisite <font color="blue">regulatory</font> approval or     may not result in <font color="blue">marketable products</font></td>
    </tr>
    <tr>
      <td>The outcome of the Phase 3 <font color="blue">SMART     </font>trial did not <font color="blue">reach <font color="blue">statistical significance</font></font> for the <font color="blue">primary endpoint</font>, which     may limit or prevent the <font color="blue">regulatory</font> approval of Xcytrin as a treatment for     <font color="blue">brain metastases</font> in <font color="blue">patients with lung cancer</font> and may result in material     harm to our business</td>
    </tr>
    <tr>
      <td>The outcomes of our other ongoing Phase 1 and Phase 2     trials  with Xcytrin for <font color="blue">additional</font> cancer <font color="blue">indications</font> may not provide     sufficient data supporting <font color="blue">advancement</font> of the <font color="blue">development</font> of Xcytrin for     these <font color="blue">additional</font> cancer <font color="blue">indications</font> and also may result in material harm to     our business</td>
    </tr>
    <tr>
      <td>To <font color="blue">generate revenue</font>, we <font color="blue">will depend on</font> FDA approval of our <font color="blue">lead product</font>         candidate, Xcytrin for the <font color="blue">potential treatment</font> of non-small cell lung         cancer patients with <font color="blue">brain metastases</font></td>
    </tr>
    <tr>
      <td>If we are unable to prepare and         <font color="blue">timely file</font> the planned NDA for this product candidate and obtain <font color="blue">FDA         </font>approval, our ability to <font color="blue">generate revenue</font> will be <font color="blue"><font color="blue">significant</font>ly delayed</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">generate revenue</font> <font color="blue">will depend on</font> the successful <font color="blue">development</font>,     <font color="blue">regulatory</font> approval and <font color="blue">commercialization</font> of Xcytrin</td>
    </tr>
    <tr>
      <td><font color="blue">In December </font>2005, we     announced the top line results of our pivotal Phase 3 <font color="blue">clinical study</font> of     Xcytrin for the <font color="blue">potential treatment</font> of non-small cell lung cancer (NSCLC)     patients with <font color="blue">brain metastases</font></td>
    </tr>
    <tr>
      <td>Although patients receiving Xcytrin had a     longer time to <font color="blue">neurologic progression</font> (TNP), the studyapstas <font color="blue">primary endpoint</font>,     the  difference  compared to patients in the <font color="blue">control arm</font> did not reach     <font color="blue">statistical significance</font></td>
    </tr>
    <tr>
      <td>Although we have received a Special Protocol Assessment (SPA) from the FDA     for our Phase 3 SMART trial, the study did not meet its <font color="blue">primary endpoint</font>     with <font color="blue">statistical significance</font></td>
    </tr>
    <tr>
      <td>Based on our <font color="blue">ongoing review</font> of the data from     the SMART trial, we plan to submit a New Drug Application (NDA) to the FDA     for the <font color="blue">potential treatment</font> of NSCLC patients with <font color="blue">brain metastases</font></td>
    </tr>
    <tr>
      <td>In     meetings  with FDA in early 2006, FDA noted that the <font color="blue">applicable review</font>     Division has not <font color="blue">approved drugs <font color="blue">based on</font></font> the results of non-pre-specified     <font color="blue">subgroup analyses</font> when the trial has failed to meet its <font color="blue">primary endpoint</font></td>
    </tr>
    <tr>
      <td>FDA discouraged the submission of an NDA <font color="blue"><font color="blue">based on</font> subset analyses from</font> the     SMART trial</td>
    </tr>
    <tr>
      <td>However, in subsequent meetings with FDA and further review of     the data, <font color="blue">the Agency </font>indicated a <font color="blue">willingness</font> to review an NDA <font color="blue">based on</font>     <font color="blue">analyses which</font> include all of the data</td>
    </tr>
    <tr>
      <td>We have limited experience in preparing, filing, and     pursuing  <font color="blue"><font color="blue">application</font>s</font>  <font color="blue">necessary</font>  to  gain  <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td>The     <font color="blue">preparation</font> of an NDA requires a great deal of effort and expertise, and if     we do not secure the <font color="blue">necessary</font> resources and hire and retain personnel     having the <font color="blue">requisite expertise</font> to prepare and submit the NDA, the filing of     the NDA would be delayed</td>
    </tr>
    <tr>
      <td>Further, if an NDA is <font color="blue">submitted by</font> the company,     there can be no assurance that it will be accepted for <font color="blue">filing by</font> the FDA If     the FDA determines after an <font color="blue">initial review</font> of the NDA that the data included     in the <font color="blue">application</font> is insufficient and not ready for <font color="blue">formal consideration</font>,     we  could  receive  a  &amp;quote refuse to file &amp;quote  notice</td>
    </tr>
    <tr>
      <td>The FDA has substantial     <font color="blue">discretion</font> in the <font color="blue">approval process</font> and <font color="blue">may disagree with</font> our <font color="blue">interpretation</font>     of the data from the Phase 3 SMART trial</td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">could also</font> require that we     conduct <font color="blue">additional</font> studies and submit that data before it <font color="blue">will reconsider</font>     our <font color="blue">application</font>, <font color="blue">which would</font> require us to expend more <font color="blue">resources than</font> we     planned or that are available to us, and <font color="blue">could <font color="blue">substantially</font> delay</font> any     approval of our <font color="blue">application</font></td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>is not <font color="blue">satisfied with data</font> included     in our NDA, we may need to expend <font color="blue">additional</font> resources or conduct <font color="blue">additional</font>     studies, including <font color="blue">clinical trials</font>, to obtain data that the FDA believes is     sufficient</td>
    </tr>
    <tr>
      <td>It is <font color="blue">also possible</font> that <font color="blue">additional</font> studies may not suffice to     make our <font color="blue">application</font> approvable</td>
    </tr>
    <tr>
      <td>Even if the NDA is accepted for <font color="blue">filing by</font>     the FDA, there can be no assurance that it would be approved in a timely     manner or at all</td>
    </tr>
    <tr>
      <td>We have incurred <font color="blue">significant</font> operating <font color="blue">losses since</font> our inception in 1991     and, as of June 30, 2006, had an <font color="blue">accumulated deficit</font> of approximately dlra288dtta9     million</td>
    </tr>
    <tr>
      <td>We expect to continue to incur substantial <font color="blue">additional</font> operating     <font color="blue">losses until such</font> time, if ever, as the <font color="blue">commercialization</font> of our products     generates  sufficient  revenues  to  cover our expenses</td>
    </tr>
    <tr>
      <td>Our achieving     <font color="blue">profitability</font>  depends  upon  our  ability,  alone  or <font color="blue">with others</font>, to     <font color="blue">successfully</font>  complete  the <font color="blue">development</font> of our products, and to obtain     required <font color="blue">regulatory</font> approvals and to <font color="blue">successfully</font> <font color="blue">manufacture</font> and market our     <font color="blue">proposed products</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">lead product</font>, Xcytrin, fails to receive <font color="blue">regulatory</font>     <font color="blue">approval on</font> a <font color="blue">timely basis</font>, or at all, our ability to become profitable     would be <font color="blue"><font color="blue">materially</font> impacted</font></td>
    </tr>
    <tr>
      <td>To date, we have not <font color="blue">generated revenue from</font>     the <font color="blue">commercial sale</font> of our products</td>
    </tr>
    <tr>
      <td>Failure to obtain product approvals or <font color="blue">comply with</font> ongoing <font color="blue"><font color="blue">government</font>al</font>         <font color="blue">regulations</font> could <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>The  <font color="blue">manufacture</font>  and  marketing  of our products and our research and     <font color="blue">development</font> <font color="blue">activities</font> are subject to extensive regulation for safety,     efficacy and quality by numerous <font color="blue">government</font> <font color="blue">authorities</font> in the <font color="blue"><font color="blue"><font color="blue">United States</font> </font>    </font>and abroad</td>
    </tr>
    <tr>
      <td>Before receiving FDA approval to market a product, we will have     to <font color="blue">demonstrate</font> to the <font color="blue">satisfaction</font> of the FDA that the product is safe and     <font color="blue">effective</font> for the <font color="blue">patient population</font> and for the diseases that will be     treated</td>
    </tr>
    <tr>
      <td>Clinical trials, and the <font color="blue">manufacturing</font> and marketing of products,     are subject to the <font color="blue">rigorous testing</font> and <font color="blue">approval process</font> of the FDA and     equivalent  foreign <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>The Federal Food, Drug and     <font color="blue">Cosmetic Act </font>and other federal, state and <font color="blue">foreign statutes</font> and <font color="blue">regulations</font>     govern  and influence the testing, <font color="blue">manufacture</font>, labeling, advertising,     <font color="blue">distribution</font>  and promotion of drugs and <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>As a result,     clinical  trials and <font color="blue">regulatory</font> approval can take a number of years to     accomplish and require the <font color="blue">expenditure</font> of substantial resources</td>
    </tr>
    <tr>
      <td>Data   obtained  from  clinical  trials  are  susceptible  to  varying     <font color="blue"><font color="blue">interpretation</font>s</font> that <font color="blue">could delay</font>, limit or prevent <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td>Data from our completed Phase 3 SMART trial may not be sufficient to obtain     <font color="blue">regulatory</font> approval of our planned NDA for the <font color="blue">potential treatment</font> of <font color="blue">NSCLC     </font>patients with <font color="blue">brain metastases</font></td>
    </tr>
    <tr>
      <td><font color="blue">Conducting </font><font color="blue">additional</font> trials will cause     <font color="blue"><font color="blue">significant</font> delays</font> in approval and consume <font color="blue">additional</font> resources and may not     be sufficient to obtain <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue"><font color="blue">may encounter</font> delays</font> or rejections based upon <font color="blue">additional</font>     <font color="blue"><font color="blue">government</font> regulation from future <font color="blue">legislation</font></font> or <font color="blue">administrative action</font> or     changes in FDA <font color="blue">policy during</font> the period of product <font color="blue">development</font>, clinical     trials and FDA <font color="blue">regulatory</font> review</td>
    </tr>
    <tr>
      <td>The fast-track designation that we have     received for our Phase 3 SMART trial of Xcytrin may not <font color="blue">actually lead</font> to a     faster <font color="blue">development</font>, <font color="blue">regulatory</font> review, or <font color="blue">approval process</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may encounter</font>     similar delays in <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td>We may be unable to obtain requisite     approvals  from the FDA and foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> and even if     obtained, such approvals may not be received on a <font color="blue">timely basis</font>, or they may     not cover the <font color="blue">clinical use</font>s that we specify</td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">regulatory</font> approval may entail ongoing <font color="blue"><font color="blue">requirement</font>s</font> for post-     <font color="blue">marketing studies</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> and marketing of drugs are subject to     continuing  FDA  and  foreign <font color="blue">regulatory</font> review and later <font color="blue">discovery</font> of     <font color="blue">previously</font> unknown problems with a product, <font color="blue">manufacture</font>r or <font color="blue">facility</font> may     result in <font color="blue">restrictions</font>, including withdrawal of the <font color="blue">product from</font> the market</td>
    </tr>
    <tr>
      <td>Any of the <font color="blue">following events</font>, if they were to occur, <font color="blue">could delay</font> or preclude     <font color="blue">us from further</font> developing, marketing or realizing full <font color="blue">commercial use</font> of     our products, which in turn would have a material adverse effect on our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font>:       * failure  to  obtain and thereafter maintain requisite <font color="blue"><font color="blue">government</font>al</font>         approvals;       * failure to obtain approvals for specific <font color="blue">indications</font> of our products         under <font color="blue">development</font>; or       * <font color="blue">identification</font> of serious and <font color="blue">unanticipated adverse</font> side effects in our         products under <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">regulatory</font> approval that we receive for a <font color="blue">product candidate may</font> be     subject to <font color="blue"><font color="blue">limitation</font>s on</font> the <font color="blue">indicated uses</font> for which the <font color="blue">product may</font> be     marketed</td>
    </tr>
    <tr>
      <td>In addition, if the FDA and/or foreign <font color="blue">regulatory</font> agencies approve     any  of our product <font color="blue">candidates</font>, the labeling, packaging, adverse event     reporting, storage, advertising and promotion of the <font color="blue">product will</font> be subject     to  extensive <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>We and the <font color="blue">manufacture</font>rs of our     product  <font color="blue">candidates</font>  must  also  comply  with  the applicable FDA Good     <font color="blue">Manufacturing </font>Practice ( &amp;quote GMP &amp;quote ) <font color="blue">regulations</font>, which include <font color="blue">quality control</font>     and <font color="blue">quality assurance <font color="blue"><font color="blue">requirement</font>s</font> as well as</font> the <font color="blue"><font color="blue">corresponding</font> maintenance</font>     of  records and <font color="blue">documentation</font></td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturing </font><font color="blue">facilities</font> are subject to     <font color="blue"><font color="blue">ongoing periodic</font> inspection by</font> the FDA and <font color="blue">corresponding</font> state agencies,     including unannounced <font color="blue">inspections</font>, and must be licensed before they can be     used in commercial <font color="blue">manufacturing</font> of our products</td>
    </tr>
    <tr>
      <td>We or our present or     future suppliers may be unable to <font color="blue">comply with</font> the applicable GMP <font color="blue">regulations</font>     and other FDA <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>Failure of our suppliers to follow     current Good <font color="blue">Manufacturing </font>Practice or other <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> may     lead to <font color="blue"><font color="blue">significant</font> delays</font> in the <font color="blue">availability</font> of products for commercial or     <font color="blue">clinical use</font> and could subject us to fines, injunctions and <font color="blue">civil penalties</font></td>
    </tr>
    <tr>
      <td>We will need substantial <font color="blue">additional</font> financing and we may have <font color="blue"><font color="blue">difficult</font>y</font>         raising needed capital in the future</td>
    </tr>
    <tr>
      <td>We have expended and <font color="blue">will continue</font> to expend substantial funds to complete     the research, <font color="blue">development</font> and <font color="blue">clinical testing</font> of our products</td>
    </tr>
    <tr>
      <td>We will     expend <font color="blue">additional</font> funds for these purposes, to establish <font color="blue">additional</font> clinical     and commercial-scale <font color="blue">manufacturing</font> <font color="blue"><font color="blue">arrangement</font>s</font> and to provide for the     marketing and <font color="blue">distribution</font> of our products</td>
    </tr>
    <tr>
      <td>Specifically, we will require     <font color="blue">additional</font>  funds to <font color="blue">commercialize</font> our product</td>
    </tr>
    <tr>
      <td>Even if we are able to     develop Xcytrin <font color="blue">successfully</font> in light of the recent results from our Phase 3     <font color="blue">clinical study</font>, we expect <font color="blue">additional</font> <font color="blue">development</font> efforts and <font color="blue">clinical trials</font>     will extend the timeline for <font color="blue">development</font> and will result in substantial     <font color="blue">additional</font> expenses</td>
    </tr>
    <tr>
      <td>We may be unable to fund these <font color="blue">efforts with</font> our current     <font color="blue">financial resources</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>funds may not be <font color="blue">available on</font> acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>If     adequate  funds  are  un<font color="blue">available on</font> a <font color="blue">timely basis</font> from <font color="blue">operations</font> or     <font color="blue">additional</font> sources of financing, we may have to delay, reduce the scope of     or <font color="blue">eliminate one</font> or more of our research or <font color="blue">development</font> programs <font color="blue">which would</font>     <font color="blue">materially</font>  and <font color="blue">adversely</font> affect our business, <font color="blue">financial condition</font> and     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We believe that our cash, cash equivalents and <font color="blue">marketable securities will</font> be     adequate to satisfy our capital needs <font color="blue">through at least</font> the <font color="blue">next twelve</font>     months</td>
    </tr>
    <tr>
      <td>We may, however, choose to raise <font color="blue">additional</font> funds before then</td>
    </tr>
    <tr>
      <td>Our     actual capital <font color="blue"><font color="blue">requirement</font>s</font> <font color="blue">will depend on</font> many factors, including:       * continued progress of our research and <font color="blue">development</font> programs;       * our  ability  to <font color="blue">establish collaborative <font color="blue"><font color="blue">arrangement</font>s</font></font> and maintain         <font color="blue">existing ones</font>;       * progress <font color="blue">with preclinical studies</font> and <font color="blue">clinical trials</font>;       * the time and <font color="blue">costs involved</font> in obtaining <font color="blue">regulatory</font> approval;       * the <font color="blue">costs involved</font> in preparing, filing, prosecuting, maintaining and         <font color="blue">enforcing patent</font> claims;       * the amount and timing of <font color="blue">capital equipment purchases</font>;       * <font color="blue">competing <font color="blue">technological</font></font> and market <font color="blue">development</font>s; and       * our ability to market and distribute our products and <font color="blue">establish new</font>         <font color="blue">licensing <font color="blue"><font color="blue">arrangement</font>s</font></font></td>
    </tr>
    <tr>
      <td>In August 2006, we <font color="blue">entered into</font> a <font color="blue">common stock</font> <font color="blue">purchase <font color="blue">agreement</font></font> with     Azimuth Opportunity Ltd, <font color="blue">which provides</font> that, upon the terms and subject to     the <font color="blue">conditions</font> set forth in the <font color="blue">purchase <font color="blue">agreement</font></font>, Azimuth is committed to     purchase  up  to dlra20 million of our <font color="blue">common stock</font>, or 4cmam189cmam337 shares,     whichever occurs first, at a discount of 5prca to 7prca, to be determined <font color="blue">based on</font>     our <font color="blue">market capitalization at</font> the start of <font color="blue">each sale period</font></td>
    </tr>
    <tr>
      <td>The term of the     <font color="blue">purchase <font color="blue">agreement</font></font> is 18 months</td>
    </tr>
    <tr>
      <td>Upon each sale of our <font color="blue">common stock</font> to     Azimuth under the <font color="blue">purchase <font color="blue">agreement</font></font>, we have also agreed to pay Reedland     Capital Partners a placement fee equal to one percent of the aggregate     <font color="blue">dollar amount</font> of <font color="blue">common stock</font> purchased by Azimuth</td>
    </tr>
    <tr>
      <td>Even though we have     <font color="blue">entered into</font> this <font color="blue">purchase <font color="blue">agreement</font></font> with Azimuth, Azimuth would not be     required to purchase our <font color="blue">common stock</font> if the price of our <font color="blue">common stock</font> falls     below dlra3dtta00 per share</td>
    </tr>
    <tr>
      <td>Furthermore, we may     decide  not  to  sell  any shares of our <font color="blue">common stock</font> pursuant to this     <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>We may seek to raise any <font color="blue">necessary</font> <font color="blue">additional</font> funds through equity or debt     financings, collaborative <font color="blue"><font color="blue">arrangement</font>s</font> with corporate partners or other     sources that may be dilutive to <font color="blue">existing <font color="blue">stockholders</font></font> or subject us to     <font color="blue">restrictive covenants</font></td>
    </tr>
    <tr>
      <td>In addition, in the event that <font color="blue">additional</font> funds are     obtained <font color="blue">through <font color="blue"><font color="blue">arrangement</font>s</font> with <font color="blue">collaborative partners</font></font> or other sources,     such  <font color="blue"><font color="blue">arrangement</font>s</font>  may require us to <font color="blue">relinquish rights</font> to some of our     <font color="blue">technologies</font>, product <font color="blue">candidates</font> or products under <font color="blue">development</font> that we would     <font color="blue">otherwise seek</font> to develop or <font color="blue">commercialize</font> ourselves</td>
    </tr>
    <tr>
      <td><font color="blue">Acceptance </font>of our products in the marketplace is uncertain, and failure to         achieve <font color="blue">market <font color="blue">acceptance</font> will harm</font> our business</td>
    </tr>
    <tr>
      <td>Even  if  approved  for marketing, our <font color="blue">products may</font> not achieve market     <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>The degree of market <font color="blue">acceptance</font> <font color="blue">will depend upon</font> a number of     factors, including:       * the receipt of <font color="blue">regulatory</font> approvals for the <font color="blue">indications</font> that we are         studying, and the <font color="blue">acceptance</font> by physicians and patients of the clinical         benefits that our <font color="blue">products may</font> offer;       * the <font color="blue">establishment</font> and <font color="blue">demonstration</font> in the <font color="blue">medical community</font> of the         safety, clinical efficacy and cost-<font color="blue">effective</font>ness of our products and         their potential advantages over existing <font color="blue">therapeutic</font> products;       * marketing and <font color="blue">distribution</font> support;       * the introduction, market penetration and <font color="blue">pricing strategies</font> of competing         and <font color="blue">future products</font>; and       * coverage and <font color="blue"><font color="blue">reimbursement</font> policies</font> of <font color="blue"><font color="blue">government</font>al</font> and other third-         party  payors  such  as  insurance  companies,  <font color="blue">health maintenance</font>         <font color="blue"><font color="blue">organization</font>s</font> and other plan <font color="blue">administrators</font></td>
    </tr>
    <tr>
      <td>Physicians, patients, payors or the <font color="blue">medical community</font> in <font color="blue">general may</font> be     unwilling to accept, purchase, utilize or recommend any of our products</td>
    </tr>
    <tr>
      <td>We may fail to <font color="blue"><font color="blue">adequately</font> protect</font> or enforce our <font color="blue"><font color="blue">intellectual</font> property</font>         rights or <font color="blue">secure rights</font> to third-party patents</td>
    </tr>
    <tr>
      <td>We <font color="blue">face risks</font> and <font color="blue">uncertainties</font> related to our <font color="blue"><font color="blue">intellectual</font> property</font> rights</td>
    </tr>
    <tr>
      <td>For example:       * we may be unable to obtain or maintain patent or other <font color="blue">intellectual</font>         <font color="blue">property protection</font> for any products or processes that we may develop;       * <font color="blue">third <font color="blue">parties may</font></font> obtain patents covering the <font color="blue">manufacture</font>, use or sale         of these products, which <font color="blue">may prevent us from</font> <font color="blue">commercializing</font> any of our         products under <font color="blue">development</font> globally or in <font color="blue">certain regions</font>; and       * any <font color="blue">future patents</font> that we may obtain may not prevent other companies         <font color="blue">from competing with us by designing</font> their products or conducting their         <font color="blue">activities</font> so as to avoid the coverage of our patents</td>
    </tr>
    <tr>
      <td>A number of third-party patent <font color="blue"><font color="blue">application</font>s</font> have <font color="blue">been published</font>, and some     have issued, relating to <font color="blue">expanded porphyrin chemistries</font></td>
    </tr>
    <tr>
      <td>It is likely that     <font color="blue">competitors</font>  and  other  third  parties have and <font color="blue">will continue</font> to file     <font color="blue"><font color="blue">application</font>s</font> for and receive patents relating to similar or even the same     <font color="blue">compositions</font>,  methods  or  designs  as  those of our products</td>
    </tr>
    <tr>
      <td>If any     third-party patent claims are asserted against our products and are upheld     as  valid  and  infringed  by our products, we could be prevented from     practicing the subject matter claimed in <font color="blue">such patents</font> and therefore from     developing or <font color="blue">commercializing</font> our products, require license(s) or have to     redesign our products or processes to avoid <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">licenses may</font>     not be available or, if available, may not be on terms acceptable to us</td>
    </tr>
    <tr>
      <td>Alternatively,  we  may be <font color="blue">unsuccessful</font> in any attempt to redesign our     products or processes to avoid <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>or other legal     <font color="blue">proceedings may</font> be <font color="blue">necessary</font> to <font color="blue">defend against</font> claims of <font color="blue">infringement</font>, to     enforce our patents, or to protect our <font color="blue">trade secrets</font>, and could result in     substantial cost to the company and diversion of our efforts</td>
    </tr>
    <tr>
      <td>We are aware of several US patents owned or <font color="blue">licensed by</font> <font color="blue">Schering AG </font>that     relate to <font color="blue"><font color="blue">pharmaceutical</font> formulations</font> and methods for <font color="blue">enhancing magnetic</font>     <font color="blue">resonance imaging</font></td>
    </tr>
    <tr>
      <td>Even though we have obtained the opinion of outside     <font color="blue">patent counsel</font> that our <font color="blue">cancer treatment compounds</font> do not infringe any     valid, unexpired claims of <font color="blue">such patents</font>, <font color="blue">Schering AG </font><font color="blue">may still choose</font> to     assert one or more of those patents</td>
    </tr>
    <tr>
      <td>If any of our products were legally     determined to be infringing a valid and enforceable claim of any of Schering     AGapstas patents, our business could be <font color="blue">materially</font> <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Further,     any <font color="blue">allegation</font> by <font color="blue">Schering AG </font>that we infringed their <font color="blue">patents would likely</font>     result in <font color="blue"><font color="blue">significant</font> legal costs</font> and require the diversion of substantial     <font color="blue"><font color="blue">management</font> resources</font></td>
    </tr>
    <tr>
      <td>We are aware that <font color="blue">Schering AG </font>has asserted patent     <font color="blue">rights against at least one</font> other company in the <font color="blue">contrast agent imaging</font>     market  and  that  a  number  of companies have <font color="blue">entered into</font> licensing     <font color="blue"><font color="blue">arrangement</font>s</font> with <font color="blue">Schering AG </font><font color="blue">with respect</font> to one or more of <font color="blue">such patents</font></td>
    </tr>
    <tr>
      <td>We cannot be certain that we would be successful in defending a lawsuit or     able to obtain a <font color="blue">license on commercially reasonable terms from</font> Schering AG,     if required</td>
    </tr>
    <tr>
      <td>We  also  rely  upon  <font color="blue">trade secrets</font>, technical know-how and continuing     <font color="blue"><font color="blue">technological</font> innovation</font> to develop and maintain our <font color="blue">competitive position</font></td>
    </tr>
    <tr>
      <td>Although we take steps to protect our <font color="blue"><font color="blue">proprietary</font> rights</font> and information,     including the use of <font color="blue">confidentiality</font> and other <font color="blue">agreement</font>s with our employees     and <font color="blue">consultants</font>, and in our academic and <font color="blue">commercial <font color="blue">relationship</font>s</font>, these     steps may be inadequate, these <font color="blue">agreement</font>s may be violated, or there may be     <font color="blue">no adequate remedy available</font> for a violation</td>
    </tr>
    <tr>
      <td>Furthermore, our <font color="blue">competitors</font>     <font color="blue">may independently</font> develop <font color="blue"><font color="blue">substantially</font> equivalent <font color="blue">proprietary</font></font> information     and  <font color="blue">techniques</font>,  reverse  engineer our information and <font color="blue">techniques</font>, or     <font color="blue">otherwise gain access</font> to our <font color="blue"><font color="blue">proprietary</font> technology</font></td>
    </tr>
    <tr>
      <td>We may be unable to     <font color="blue">meaningfully protect</font> our rights in unpatented <font color="blue"><font color="blue">proprietary</font> technology</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">rely heavily on <font color="blue">third parties</font></font> for product and clinical <font color="blue">development</font> of our         products</td>
    </tr>
    <tr>
      <td>We <font color="blue">currently depend heavily</font> and <font color="blue">will depend heavily</font> in the <font color="blue">future on third</font>     parties for support in product <font color="blue">development</font> and clinical <font color="blue">development</font> of our     products</td>
    </tr>
    <tr>
      <td>The  <font color="blue">termination</font>  of  a  <font color="blue">significant</font> number of our existing     collaborative <font color="blue"><font color="blue">arrangement</font>s</font>, or our <font color="blue">inability</font> to establish and maintain     collaborative <font color="blue"><font color="blue">arrangement</font>s</font> could have a material adverse effect on our     ability to complete clinical <font color="blue">development</font> of our products</td>
    </tr>
    <tr>
      <td>We rely on contract clinical research <font color="blue"><font color="blue">organization</font>s</font>, or CROs, for various     aspects of our clinical <font color="blue">development</font> <font color="blue">activities</font> including clinical trial     monitoring, data <font color="blue">collection</font> and data <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>As a result, we have had     and continue to have less control over the conduct of <font color="blue">clinical trials</font>, the     timing and <font color="blue">completion</font> of the trials, the required reporting of adverse     events and the <font color="blue">management</font> of data developed through the <font color="blue">trial than would</font> be     the case if we were <font color="blue">relying entirely upon</font> our own staff</td>
    </tr>
    <tr>
      <td>Although we rely on     CROs  to  conduct  some of our <font color="blue">clinical trials</font>, we are responsible for     <font color="blue">confirming</font> that each of our <font color="blue">clinical trials</font> is conducted in <font color="blue">accordance</font> with     the  <font color="blue">investigational</font>  plan and protocol</td>
    </tr>
    <tr>
      <td>Moreover, the FDA and foreign     <font color="blue">regulatory</font> agencies require us to <font color="blue">comply with</font> <font color="blue">regulations</font> and standards,     commonly referred to as good clinical practices, for conducting, recording     and reporting the results of <font color="blue">clinical trials</font> to assure that the data and     results  are credible and accurate and that the trial <font color="blue">participants</font> are     <font color="blue"><font color="blue">adequately</font> protect</font>ed</td>
    </tr>
    <tr>
      <td>Our <font color="blue">reliance on <font color="blue">third parties</font></font> does not <font color="blue">relieve us</font> of     these <font color="blue">responsibilities</font> and <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>Outside <font color="blue">parties may</font> have staffing <font color="blue">difficult</font>ies, may undergo changes in     priorities or may become financially distressed, <font color="blue">adversely</font> affecting their     <font color="blue">willingness</font> or ability to conduct our trials</td>
    </tr>
    <tr>
      <td>We may experience unexpected     <font color="blue">cost increases</font> that are beyond our control</td>
    </tr>
    <tr>
      <td>Any failure of such CROs to     <font color="blue">successfully</font> accomplish clinical trial monitoring, data <font color="blue">collection</font> and data     <font color="blue">management</font> and the other services they provide for us in a <font color="blue">timely manner</font> and     in compliance with <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> could have a material adverse     effect on our ability to complete clinical <font color="blue">development</font> of our products and     obtain <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>Problems with the <font color="blue">timeliness</font> or quality of the     work of a CRO <font color="blue">may lead us</font> to seek to terminate the <font color="blue">relationship</font> and use an     <font color="blue">alternate service provider</font></td>
    </tr>
    <tr>
      <td>However, making such changes may be costly and     may delay our trials, and contractual <font color="blue">restrictions</font> may make such a change     <font color="blue">difficult</font>  or  impossible</td>
    </tr>
    <tr>
      <td>Additionally, it may be <font color="blue">difficult</font> to find a     <font color="blue">replacement <font color="blue">organization</font></font> that can conduct our trials in an acceptable manner     and at an acceptable cost</td>
    </tr>
    <tr>
      <td>We lack the resources, capability and experience <font color="blue">necessary</font> to <font color="blue">manufacture</font>         <font color="blue"><font color="blue">pharmaceutical</font>s</font> and thus rely heavily upon contract <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td>We have no <font color="blue">manufacturing</font> <font color="blue">facilities</font> and we <font color="blue">currently rely on <font color="blue">third parties</font></font>     for <font color="blue">manufacturing</font> and storage <font color="blue">activities</font> related to all of our products in     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">manufacturing</font> strategy presents the <font color="blue">following risks</font>:       * delays in scale-up to quantities needed for multiple <font color="blue">clinical trials</font>, or         failure to <font color="blue">manufacture</font> such quantities to our <font color="blue">specifications</font>, or deliver         <font color="blue">such quantities on</font> the dates we require, could cause delay or suspension         of <font color="blue">clinical trials</font>, <font color="blue">regulatory</font> submissions and <font color="blue">commercialization</font> of our         products in <font color="blue">development</font>;       * there is no guarantee that the supply of <font color="blue">clinical materials</font> can be         maintained during the clinical <font color="blue">development</font> of our product <font color="blue">candidates</font>;       * our current and future <font color="blue">manufacture</font>rs are subject to <font color="blue">ongoing periodic</font>         unannounced <font color="blue">inspections</font> by the FDA and <font color="blue">corresponding</font> <font color="blue">regulatory</font> agencies         for  compliance  with strictly enforced current Good <font color="blue">Manufacturing </font>        Practice  and  similar  foreign  standards</td>
    </tr>
    <tr>
      <td>Failure to pass these         <font color="blue">inspections</font> could have a material adverse effect on our ability to         produce our products to support our <font color="blue">operations</font>;       * if we need to change to other commercial <font color="blue">manufacturing</font> <font color="blue">contractors</font>,         there  is  no  guarantee that we will be able to locate a suitable         <font color="blue">replacement contractor</font></td>
    </tr>
    <tr>
      <td>The FDA and comparable foreign <font color="blue">regulators</font> must         approve material <font color="blue">manufacture</font>d by these <font color="blue">contractors</font> prior to our use</td>
    </tr>
    <tr>
      <td>This would require new testing and compliance <font color="blue">inspections</font></td>
    </tr>
    <tr>
      <td>The new         <font color="blue">manufacture</font>rs would have to <font color="blue">practice <font color="blue">substantially</font> equivalent processes</font>         for the production of our products;       * our current <font color="blue">manufacture</font>rs might not be able to fulfill our commercial         needs, <font color="blue">which would</font> require us to seek new <font color="blue">manufacturing</font> <font color="blue"><font color="blue">arrangement</font>s</font> and         may result in substantial delays in <font color="blue">meeting market demand</font>; and       * any <font color="blue">disruption</font> of the ability of our <font color="blue">manufacturing</font> <font color="blue">contractors</font> to supply         <font color="blue">necessary</font> quantities of our <font color="blue">products could</font> have a material adverse         effect on our ability to support our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Any of these factors <font color="blue">could delay</font> <font color="blue">clinical trials</font> or <font color="blue">commercialization</font> of our     products under <font color="blue">development</font> and entail higher costs</td>
    </tr>
    <tr>
      <td>We lack marketing, <font color="blue">distribution</font> and sales experience</td>
    </tr>
    <tr>
      <td>We  have no experience marketing, selling or <font color="blue">distributing products</font> and     <font color="blue">currently lack</font> the <font color="blue">internal capability</font> to do so</td>
    </tr>
    <tr>
      <td>If any of our product     <font color="blue">candidates</font>  are  approved  by the FDA, we will need a <font color="blue"><font color="blue">sales force</font> with</font>     <font color="blue">technical expertise prior</font> to the <font color="blue">commercialization</font> of any of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We have no experience in developing, training or managing a     <font color="blue">sales force</font></td>
    </tr>
    <tr>
      <td>We will incur substantial <font color="blue">additional</font> expenses in developing,     training and <font color="blue">managing such</font> an <font color="blue">organization</font></td>
    </tr>
    <tr>
      <td>We may be unable to <font color="blue">build such</font> a     <font color="blue">sales force</font>, the cost of <font color="blue"><font color="blue">establishing</font> such</font> a <font color="blue">sales force</font> may exceed any     product  revenues,  or  our  <font color="blue">direct marketing</font> and <font color="blue">sales efforts may</font> be     <font color="blue">unsuccessful</font></td>
    </tr>
    <tr>
      <td>In  addition, we <font color="blue">compete with</font> many other companies that     currently have extensive and well-funded marketing and sales <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our     marketing and <font color="blue">sales efforts may</font> be unable to compete <font color="blue">successfully</font> against     those of such other companies</td>
    </tr>
    <tr>
      <td>For some <font color="blue">market opportunities</font>, including     those outside the <font color="blue">United States</font>, we will need to enter into co-promotion or     other <font color="blue">licensing <font color="blue"><font color="blue">arrangement</font>s</font></font> with larger <font color="blue">pharmaceutical</font> or <font color="blue">biotechnology</font>     firms in order to increase the <font color="blue">commercial success</font> of our products</td>
    </tr>
    <tr>
      <td>To the     extent we enter into co-promotion or other licensing <font color="blue">agreement</font>s, our product     revenues are likely to be lower than if we <font color="blue">directly marketed</font> and sold our     products, and some or all of the revenues we receive <font color="blue">will depend upon</font> the     efforts of <font color="blue">third parties</font>, which may not be successful and may not be within     our control</td>
    </tr>
    <tr>
      <td>If we are unable to enter into co-promotion or other licensing     <font color="blue">agreement</font>s on acceptable terms or at all, we may not be able to <font color="blue">successfully</font>     <font color="blue">commercialize</font> our existing and future product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If we are not     successful in <font color="blue">commercializing</font> our existing and future product <font color="blue">candidates</font>,     <font color="blue">either on</font> our own or <font color="blue">through <font color="blue">collaborations</font> with one</font> or more <font color="blue">third parties</font>,     our <font color="blue">future product revenue will suffer</font> and we may incur <font color="blue">significant</font> losses</td>
    </tr>
    <tr>
      <td>If we lose or are unable to hire and retain <font color="blue">qualified personnel</font>, then we may         not be able to develop our products or processes and obtain the required         <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td>We are <font color="blue">highly dependent on qualified scientific</font> and <font color="blue">management</font> personnel</td>
    </tr>
    <tr>
      <td>We     will need to expand and <font color="blue">effective</font>ly manage our managerial, operational,     financial, <font color="blue">development</font> and other resources in order to <font color="blue">successfully</font> pursue     our research, <font color="blue">development</font> and <font color="blue">commercialization</font> efforts for our existing and     future product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">preparation</font> of our planned NDA requires     <font color="blue">highly specialized skills</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends on</font> our <font color="blue">continued ability</font> to     attract, retain and motivate highly qualified <font color="blue">management</font> and pre-clinical     and <font color="blue">clinical personnel</font></td>
    </tr>
    <tr>
      <td>We will need to hire <font color="blue">additional</font> personnel as we     continue to expand our research and <font color="blue">development</font> <font color="blue">activities</font>, prepare our     planed NDA for filing, and build a sales and marketing function in the     <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">face intense <font color="blue">competition</font> from</font> other companies and research and academic     <font color="blue">institutions</font> for <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td>We may not be able to attract or     retain qualified <font color="blue">management</font> and <font color="blue">scientific personnel</font> in the future due to     the  intense  <font color="blue">competition</font> for <font color="blue">qualified personnel</font> among <font color="blue">biotechnology</font>,     <font color="blue">pharmaceutical</font> and other <font color="blue">businesses</font>, particularly in the San Francisco,     <font color="blue">California </font>area</td>
    </tr>
    <tr>
      <td>If we lose an <font color="blue">executive officer</font>, a manager of one of our     programs, or a <font color="blue">significant</font> number of any of our staff or are unable to hire     and  retain  qualified  personnel,  then  our  ability  to develop and     <font color="blue">commercialize</font>  our products and processes, raise <font color="blue">additional</font> capital or     implement our business <font color="blue">strategy may</font> be <font color="blue">adversely</font> affected or prevented</td>
    </tr>
    <tr>
      <td>In     particular, if we lose any members of our senior <font color="blue">management</font> team, we may not     be able to <font color="blue">find suitable replacements</font> in a <font color="blue">timely fashion</font> or at all and our     business may be <font color="blue">harmed as</font> a result</td>
    </tr>
    <tr>
      <td>Our business is subject to risks associated with international <font color="blue">operations</font>         and <font color="blue">collaborations</font></td>
    </tr>
    <tr>
      <td>The laws of <font color="blue">foreign countries</font> do not protect our <font color="blue"><font color="blue">intellectual</font> property</font>     rights to the <font color="blue">same extent as</font> do the laws of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>In countries     where we do not have and/or have not applied for <font color="blue">patents on</font> our products, we     will  be  unable  to <font color="blue">prevent others from</font> developing or selling similar     products</td>
    </tr>
    <tr>
      <td>In addition, in <font color="blue">jurisdictions outside</font> the <font color="blue"><font color="blue">United States</font> </font>where we     acquire <font color="blue">patent rights</font>, we may be unable to <font color="blue">prevent unlicensed parties from</font>     selling or <font color="blue">importing products</font> or <font color="blue"><font color="blue">technologies</font> derived elsewhere using</font> our     <font color="blue">patented technology</font></td>
    </tr>
    <tr>
      <td>Until we or our licensees obtain the required <font color="blue">regulatory</font> approvals for     <font color="blue"><font color="blue">pharmaceutical</font>s</font> in any <font color="blue">specific foreign country</font>, we or our <font color="blue">licensees will</font> be     unable to sell these products in that country</td>
    </tr>
    <tr>
      <td><font color="blue">International </font><font color="blue">regulatory</font>     <font color="blue">authorities</font> have <font color="blue">imposed numerous</font> and varying <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> and     the <font color="blue">approval procedures</font> can involve <font color="blue">additional</font> testing</td>
    </tr>
    <tr>
      <td>Approval by one     <font color="blue">regulatory</font>  authority does not <font color="blue">ensure approval by</font> any other <font color="blue">regulatory</font>     authority</td>
    </tr>
    <tr>
      <td>We may be subject to damages resulting from claims that our employees or we         have <font color="blue">wrongfully used</font> or disclosed alleged <font color="blue">trade secrets</font> of their former         employers</td>
    </tr>
    <tr>
      <td>Many of our employees were <font color="blue">previously</font> employed at <font color="blue">universities</font> or other     <font color="blue">biotechnology</font> or <font color="blue">pharmaceutical</font> companies, including our <font color="blue">competitors</font> or     potential <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Although no claims <font color="blue">against us</font> are currently pending,     we may be subject to claims that these employees or we have <font color="blue">inadvertently</font> or     otherwise used or disclosed <font color="blue">trade secrets</font> or other <font color="blue">proprietary</font> information     of their <font color="blue">former employers</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>may be <font color="blue">necessary</font> to <font color="blue">defend against</font>     these claims</td>
    </tr>
    <tr>
      <td>If we fail in <font color="blue">defending such</font> claims, in addition to paying     <font color="blue">monetary damages</font>, we may lose valuable <font color="blue"><font color="blue">intellectual</font> property</font> rights or     personnel</td>
    </tr>
    <tr>
      <td>A loss of <font color="blue">key research personnel</font> or their work <font color="blue">product could</font>     hamper or prevent our ability to <font color="blue">commercialize</font> certain potential drugs,     which  could  <font color="blue">severely harm</font> our business</td>
    </tr>
    <tr>
      <td>Even if we are successful in     <font color="blue">defending against</font> these claims, <font color="blue"><font color="blue">litigation</font> could</font> result in substantial costs     and be a <font color="blue">distraction</font> to <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>We  may  need  to implement <font color="blue">additional</font> finance and <font color="blue">accounting systems</font>,         procedures and controls to <font color="blue">satisfy new</font> reporting <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>As  a  public  reporting  company,  we are required to <font color="blue">comply with</font> the     Sarbanes-Oxley Act of 2002, including Section 404, and the related rules and     <font color="blue">regulations</font> of the Securities and Exchange Commission, including expanded     <font color="blue">disclosures</font>  and  <font color="blue">accelerated</font>  reporting <font color="blue"><font color="blue">requirement</font>s</font> and more complex     <font color="blue">accounting rules</font></td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with Section 404 and other <font color="blue"><font color="blue">requirement</font>s</font> will     increase our costs and require <font color="blue">additional</font> <font color="blue"><font color="blue">management</font> resources</font></td>
    </tr>
    <tr>
      <td>We may need     to  continue  to  implement <font color="blue">additional</font> finance and <font color="blue">accounting systems</font>,     procedures and controls to <font color="blue">satisfy new</font> reporting <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>While we have     been able to complete a favorable <font color="blue">assessment as</font> to the adequacy of our     <font color="blue">internal control over financial</font> reporting for our <font color="blue">fiscal year</font> ending <font color="blue">June     </font>30, 2006, there is no assurance that <font color="blue">future assessments</font> of the adequacy of     our <font color="blue">internal control over financial</font> reporting will be favorable</td>
    </tr>
    <tr>
      <td>If we are     unable to obtain <font color="blue">future unqualified</font> reports as to the <font color="blue">effective</font>ness of our     <font color="blue">internal control over financial</font> reporting, <font color="blue">investors could lose confidence</font>     in the <font color="blue">reliability</font> of our <font color="blue">internal controls over financial</font> reporting, which     could <font color="blue">adversely</font> affect our stock price</td>
    </tr>
    <tr>
      <td>Our <font color="blue">corporate compliance program cannot guarantee</font> that we are in compliance         with all potentially applicable <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font>, <font color="blue">manufacturing</font>, pricing, sales, coverage and <font color="blue">reimbursement</font>     of  our products, together with our general <font color="blue">operations</font>, are subject to     extensive <font color="blue">regulation by federal</font>, state and other <font color="blue">authorities</font> within the     <font color="blue"><font color="blue">United States</font> </font>and numerous entities outside of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>While we     have developed and instituted a corporate compliance program <font color="blue">based on</font> what     we believe are the current best practices, we <font color="blue">cannot provide</font> any assurance     that <font color="blue"><font color="blue">government</font>al</font> <font color="blue">authorities</font> will find that our business <font color="blue">practices comply</font>     with  current  or <font color="blue">future administrative</font> or judicial <font color="blue"><font color="blue">interpretation</font>s</font> of     <font color="blue">potentially applicable laws</font> and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">comply with</font> any     of these laws and <font color="blue">regulations</font>, we could be subject to a range of <font color="blue">regulatory</font>     actions, including suspension or <font color="blue">termination</font> of <font color="blue">clinical trials</font>, the failure     to  approve  a  product  candidate,  <font color="blue">restrictions</font>  on  our products or     <font color="blue">manufacturing</font> processes, withdrawal of <font color="blue">products from</font> the market, <font color="blue">significant</font>     fines, or other sanctions or <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">facility</font> in <font color="blue">California </font>is located near an earthquake fault, and an         earthquake or other types of <font color="blue">natural disasters</font> or <font color="blue">resource shortages</font>         <font color="blue">could disrupt</font> our <font color="blue">operations</font> and <font color="blue">adversely</font> affect results</td>
    </tr>
    <tr>
      <td><font color="blue">Important </font><font color="blue">documents</font> and records, such as hard copies of our <font color="blue">laboratory books</font>     and  records for our drug <font color="blue">candidates</font> and compounds, are located in our     <font color="blue">corporate headquarters at</font> a <font color="blue">single location</font> in Sunnyvale, California, which     is near <font color="blue">active earthquake zones</font></td>
    </tr>
    <tr>
      <td>We do not have a formal business <font color="blue">continuity</font>     or <font color="blue">disaster recovery</font> plan, and <font color="blue">could therefore</font> experience a <font color="blue">significant</font>     business  <font color="blue">interruption</font>  in the event of a natural disaster, such as an     earthquake, drought or flood, or <font color="blue">localized extended outages</font> of critical     utilities or <font color="blue">transportation systems</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">California </font>from time to     time has experienced shortages of water, electric power and <font color="blue">natural gas</font></td>
    </tr>
    <tr>
      <td>Future shortages and conservation measures <font color="blue">could disrupt</font> our <font color="blue">operations</font> and     cause expense, thus <font color="blue">adversely</font> affecting our business and financial results</td>
    </tr>
    <tr>
      <td>If  we <font color="blue">sell shares</font> of our <font color="blue">common stock</font> under our <font color="blue">equity line</font> of credit         <font color="blue">arrangement</font> or in other future financings, existing <font color="blue">common stock</font>holders         will experience <font color="blue">immediate dilution</font> and, as a result, our <font color="blue">stock price may</font>         go down</td>
    </tr>
    <tr>
      <td>We  may from time to time issue <font color="blue">additional</font> shares of <font color="blue">common stock</font> at a     <font color="blue">discount from</font> the <font color="blue">current trading price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>As a result,     our existing <font color="blue">common stock</font>holders will experience <font color="blue">immediate dilution</font> upon the     purchase  of any shares of our <font color="blue">common stock</font> sold at such discount</td>
    </tr>
    <tr>
      <td>For     example, in August 2006, we <font color="blue">entered into</font> a <font color="blue">common stock</font> <font color="blue">purchase <font color="blue">agreement</font></font>     with Azimuth Opportunity Ltd, <font color="blue">which provides</font> that, upon the terms and     subject to the <font color="blue">conditions</font> set forth in the <font color="blue">purchase <font color="blue">agreement</font></font>, Azimuth is     committed to <font color="blue">purchase up</font> to dlra20 million of our <font color="blue">common stock</font>, or 4cmam189cmam337     shares, whichever occurs first, at a discount of 5prca to 7prca, to be determined     <font color="blue">based on</font> our <font color="blue">market capitalization at</font> the start of <font color="blue">each sale period</font></td>
    </tr>
    <tr>
      <td>The     term of the <font color="blue">purchase <font color="blue">agreement</font></font> is 18 months</td>
    </tr>
    <tr>
      <td>Upon each sale of our common     stock to Azimuth under the <font color="blue">purchase <font color="blue">agreement</font></font>, we have also agreed to pay     Reedland  Capital Partners a placement fee equal to one percent of the     aggregate <font color="blue">dollar amount</font> of <font color="blue">common stock</font> purchased by Azimuth</td>
    </tr>
    <tr>
      <td>Our existing     <font color="blue">common stock</font>holders will experience <font color="blue">immediate dilution</font> upon the purchase of     any shares of our <font color="blue">common stock</font> by Azimuth</td>
    </tr>
    <tr>
      <td>In  addition,  as  <font color="blue">opportunities present themselves</font>, we <font color="blue">may enter into</font>     financing or similar <font color="blue"><font color="blue">arrangement</font>s</font> in the future, including the issuance of     debt securities, preferred stock or <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If we issue <font color="blue">common stock</font>     or securities convertible into <font color="blue">common stock</font>, our <font color="blue">common stock</font>holders will     experience dilution</td>
    </tr>
    <tr>
      <td>Anti-takeover provisions in our charter <font color="blue">documents</font> and <font color="blue">Delaware </font>law could         prevent or delay a change in control</td>
    </tr>
    <tr>
      <td>Our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and bylaws may discourage, delay or prevent     a  merger or <font color="blue">acquisition</font> that a <font color="blue">stockholder may</font> consider favorable</td>
    </tr>
    <tr>
      <td>In     addition, provisions of the <font color="blue">Delaware </font>General Corporation Law <font color="blue">also restrict</font>     certain business combinations with interested <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>These provisions     are intended to <font color="blue">encourage potential acquirers</font> to <font color="blue">negotiate with us</font> and allow     our board of <font color="blue">directors</font> the <font color="blue">opportunity</font> to consider <font color="blue">alternative proposals</font> in     the interest of <font color="blue">maximizing stockholder value</font></td>
    </tr>
    <tr>
      <td>However, these <font color="blue">prohibitions</font>     may also discourage <font color="blue">acquisition</font> proposals or delay or prevent a change in     control, which could harm our stock price</td>
    </tr>
    <tr>
      <td>Risks Related to Our Industry     We <font color="blue">face rapid <font color="blue">technological</font></font> change and intense <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">pharmaceutical</font>  industry  is  subject  to  rapid  and substantial     <font color="blue">technological</font> change</td>
    </tr>
    <tr>
      <td><font color="blue">Therapies </font><font color="blue">designed by</font> other companies to treat the     <font color="blue">conditions</font> that are the focus of our products are currently in clinical     trials</td>
    </tr>
    <tr>
      <td><font color="blue">Developments </font><font color="blue">by others may</font> render our products under <font color="blue">development</font> or     <font color="blue"><font color="blue">technologies</font> noncompetitive</font> or obsolete, or we may be unable to keep pace     with <font color="blue">technological</font> <font color="blue">development</font>s or other <font color="blue">market factors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Technological     </font><font color="blue">competition</font> in the industry from <font color="blue">pharmaceutical</font> and <font color="blue">biotechnology</font> companies,     <font color="blue">universities</font>, <font color="blue"><font color="blue">government</font>al</font> entities and <font color="blue">others diversifying into</font> the field     is  intense  and  is expected to increase</td>
    </tr>
    <tr>
      <td>Many of these entities have     <font color="blue">significant</font>ly greater research and <font color="blue">development</font> <font color="blue">capabilities</font> than we do, as     well as <font color="blue">substantially</font> more marketing, sales, <font color="blue">manufacturing</font>, financial and     managerial resources</td>
    </tr>
    <tr>
      <td>These entities represent <font color="blue">significant</font> <font color="blue">competition</font> for     us</td>
    </tr>
    <tr>
      <td><font color="blue">Acquisitions  </font>of,  or investments in, competing <font color="blue">pharmaceutical</font> or     <font color="blue">biotechnology</font>  companies  by  large  <font color="blue">corporations</font>  could increase such     <font color="blue">competitors</font> &amp;apos  financial, marketing, <font color="blue">manufacturing</font> and other resources</td>
    </tr>
    <tr>
      <td>In     addition, we may experience <font color="blue">competition</font> from companies that have acquired or     may acquire technology from <font color="blue">universities</font> and other research <font color="blue">institutions</font></td>
    </tr>
    <tr>
      <td>As     these companies develop their <font color="blue">technologies</font>, they may develop <font color="blue">proprietary</font>     positions that <font color="blue">compete with</font> our products</td>
    </tr>
    <tr>
      <td>We are engaged in the <font color="blue">development</font> of novel <font color="blue">therapeutic</font> <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>As a     result, our resources are limited and we may experience technical <font color="blue">challenges</font>     inherent in such novel <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>have developed or are in the process of developing <font color="blue">technologies</font>     that are, or in the <font color="blue">future may</font> be, the basis for <font color="blue">competitive products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Some     </font>of  these <font color="blue">products may</font> have an entirely <font color="blue">different</font> approach or means of     accomplishing similar <font color="blue">therapeutic</font> effects than our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font>     may develop products that are safer, more <font color="blue">effective</font> or <font color="blue">less costly than</font> our     products and, therefore, present a <font color="blue">serious competitive threat</font> to our product     offerings</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may price their products below ours, may receive     better coverage and/or <font color="blue">reimbursement</font> or may have products that are more cost     <font color="blue">effective</font> than ours</td>
    </tr>
    <tr>
      <td>The widespread <font color="blue">acceptance</font> of therapies that are <font color="blue">alternatives</font> to ours may     limit market <font color="blue">acceptance</font> of our <font color="blue">products even</font> if <font color="blue"><font color="blue">commercialize</font>d</font></td>
    </tr>
    <tr>
      <td>The diseases     for which we are developing our <font color="blue">therapeutic</font> products can also be treated, in     the case of cancer, by surgery, radiation, biologics and <font color="blue">chemotherapy</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">treatments</font> are <font color="blue">widely accepted</font> in the <font color="blue">medical community</font> and have a long     history of use</td>
    </tr>
    <tr>
      <td>The <font color="blue">established use</font> of these competitive <font color="blue">products may</font> limit     the  potential  for  our  products to receive widespread <font color="blue">acceptance</font> if     <font color="blue"><font color="blue">commercialize</font>d</font></td>
    </tr>
    <tr>
      <td>The price of our <font color="blue">common stock</font> may be volatile</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">market price</font>s</font> for securities of <font color="blue">biotechnology</font> companies, including ours,     have <font color="blue">historically been highly volatile</font></td>
    </tr>
    <tr>
      <td>Our stock, like that of many other     companies, has from time to time experienced <font color="blue">significant</font> price and volume     <font color="blue">fluctuations unrelated</font> to operating performance</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our     common  stock may fluctuate <font color="blue">significant</font>ly due to a variety of factors,     including:       * the progress and results of our pre<font color="blue">clinical testing</font> and <font color="blue">clinical trials</font>;       * <font color="blue">quarterly fluctuations</font> in our financial results;       * the <font color="blue">development</font> of <font color="blue"><font color="blue">technological</font> innovation</font>s or new <font color="blue">therapeutic</font> products         by us, our <font color="blue">competitors</font> or others;       * changes in <font color="blue"><font color="blue">government</font>al</font> regulation;       * <font color="blue">development</font>s  in  patent  or  other  <font color="blue"><font color="blue">proprietary</font> rights</font> by us, our         <font color="blue">competitors</font> or others;       * <font color="blue">development</font>s and/or announcements by us, our <font color="blue">competitors</font> or others;       * <font color="blue">litigation</font>;       * public  concern  as to the safety of products developed by us, our         <font color="blue">competitors</font> or others;       * <font color="blue">departure</font> of <font color="blue">key personnel</font>;       * ability to <font color="blue">manufacture</font> our products to <font color="blue">commercial standards</font>;       * changes in the structure of <font color="blue">healthcare payment systems</font> and the coverage         and <font color="blue"><font color="blue">reimbursement</font> policies</font> of <font color="blue"><font color="blue">government</font>al</font> and other third-party payors;       * our ability to <font color="blue">successfully</font> <font color="blue">commercialize</font> our products if they are         approved;       * <font color="blue">comments by securities analysts</font>; and       * general market <font color="blue">conditions</font> in our industry</td>
    </tr>
    <tr>
      <td>In addition, if any of the <font color="blue">risks described</font> in this section entitled  &amp;quote Risk     Factors &amp;quote  actually occur, <font color="blue">there could</font> be a dramatic and material adverse     <font color="blue">impact on</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If our products are not <font color="blue">accepted by</font> the market or if users of our products         are unable to obtain <font color="blue">adequate coverage</font> of and <font color="blue">reimbursement</font> for our         <font color="blue">products from</font> <font color="blue">government</font> and other third-party payors, our revenues and         <font color="blue">profitability</font> will suffer</td>
    </tr>
    <tr>
      <td>Our  ability to <font color="blue">commercialize</font> our products <font color="blue">successfully</font> will depend in     <font color="blue">significant</font>  part  on  the extent to <font color="blue">which appropriate coverage</font> of and     <font color="blue">reimbursement</font> for our products and related <font color="blue">treatments</font> are obtained from     <font color="blue"><font color="blue">government</font>al</font> <font color="blue">authorities</font>, private health insurers and other <font color="blue"><font color="blue">organization</font>s</font>,     such as HMOs</td>
    </tr>
    <tr>
      <td>Third-party payors are <font color="blue">increasingly challenging</font> the prices     charged for <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot provide</font> any assurances     that  third- party payors will consider our products cost-<font color="blue">effective</font> or     <font color="blue">provide coverage</font> of and <font color="blue">reimbursement</font> for our products, in whole or in part</td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainty </font>exists as to the coverage and <font color="blue">reimbursement</font> status of newly     approved <font color="blue">medical products</font> and services and newly approved <font color="blue">indications</font> for     <font color="blue">existing products</font></td>
    </tr>
    <tr>
      <td>Third-party <font color="blue">payors may</font> conclude that our products are     less safe, less clinically <font color="blue">effective</font>, or less cost-<font color="blue">effective</font> than existing     products, and third-party <font color="blue">payors may</font> not approve our products for coverage     and <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>If we are unable to obtain <font color="blue">adequate coverage</font> of and     <font color="blue">reimbursement</font> for our <font color="blue">products from</font> third-party payors, physicians may limit     how much or under what <font color="blue">circumstances</font> they <font color="blue">will prescribe</font> or <font color="blue">administer them</font></td>
    </tr>
    <tr>
      <td>Such reduction or <font color="blue">limitation</font> in use of our <font color="blue">products could</font> cause our sales to     suffer</td>
    </tr>
    <tr>
      <td>Even if third-party payors make <font color="blue">reimbursement</font> available, payment     <font color="blue">levels may</font> not be sufficient to make the sale of our <font color="blue">products profitable</font></td>
    </tr>
    <tr>
      <td>Also, the trend towards managed health care in the <font color="blue"><font color="blue">United States</font> </font>and the     <font color="blue">concurrent growth</font> of <font color="blue"><font color="blue">organization</font>s</font> such as HMOs, <font color="blue">which could control</font> or     <font color="blue">significant</font>ly influence the purchase of <font color="blue">medical services</font> and products, may     result in in<font color="blue">adequate coverage</font> of and <font color="blue">reimbursement</font> for our products</td>
    </tr>
    <tr>
      <td><font color="blue">Many     </font>third- party payors, including in particular HMOs, are <font color="blue">pursuing various ways</font>     to  reduce  <font color="blue">pharmaceutical</font>  costs, including, for instance, the use of     <font color="blue">formularies</font></td>
    </tr>
    <tr>
      <td>The  market  for  our <font color="blue">products depends on access</font> to such     <font color="blue">formularies</font>, which are lists of <font color="blue">medications</font> for which third-party payors     provide <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">formularies</font> are increasingly restricted, and     <font color="blue">pharmaceutical</font> companies face <font color="blue">significant</font> <font color="blue">competition</font> in their efforts to     place their products on <font color="blue">formularies</font> of HMOs and other third-party payors</td>
    </tr>
    <tr>
      <td>This increased <font color="blue">competition</font> has led to a <font color="blue">downward pricing pressure</font> in the     industry</td>
    </tr>
    <tr>
      <td>The  cost  <font color="blue">containment measures</font> that third-party payors are     <font color="blue">instituting could</font> have a material adverse effect on our ability to operate     profitably</td>
    </tr>
    <tr>
      <td><font color="blue">Current  </font>health  care  laws  and <font color="blue">regulations</font> and <font color="blue">future <font color="blue">legislative</font></font> or         <font color="blue">regulatory</font> changes to the <font color="blue">healthcare system</font>         may affect our ability to sell our <font color="blue">products profitably</font></td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, there have been a number of <font color="blue">legislative</font> and <font color="blue">regulatory</font>     proposals to change the <font color="blue">healthcare system</font> in ways that <font color="blue">could affect</font> our     <font color="blue">future revenues</font> and <font color="blue">profitability</font>, and the <font color="blue">future revenues</font> and <font color="blue">profitability</font>     of our potential customers, suppliers and <font color="blue">collaborative partners</font>, and the     <font color="blue">availability</font> of capital</td>
    </tr>
    <tr>
      <td>Federal and state lawmakers regularly propose and,     at times, enact <font color="blue">legislation</font> that would result in <font color="blue">significant</font> changes to the     <font color="blue">healthcare system</font> and, in particular, that are intended to contain or reduce     the  costs of <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td>For example, the <font color="blue"><font color="blue">Medicare  </font>   </font>Prescription Drug, Improvement, and Modernization Act of 2003, or MMA, could     <font color="blue">significant</font>ly influence the manner in which <font color="blue">pharmaceutical</font> products are     prescribed and purchased and will impact <font color="blue">reimbursement</font> for our products,     which  could result in a reduction in demand for our products</td>
    </tr>
    <tr>
      <td><font color="blue">The MMA     </font>established a new <font color="blue">reimbursement</font> methodology for <font color="blue">certain <font color="blue">drugs furnished</font></font> in     <font color="blue"><font color="blue">hospital outpatient</font> <font color="blue">departments</font></font> and physicians &amp;apos  offices which is <font color="blue">based on</font>     the <font color="blue">average sales price</font>, or ASP, of the product</td>
    </tr>
    <tr>
      <td><font color="blue">Application of the ASP     </font><font color="blue">reimbursement</font> methodology has resulted in a decrease in the <font color="blue">reimbursement</font>     levels  for  certain  oncology  <font color="blue">drugs furnished</font> in <font color="blue">hospital outpatient</font>     <font color="blue">departments</font>  and  physicians &amp;apos  offices</td>
    </tr>
    <tr>
      <td>As implemented in a <font color="blue">recent rule</font>     <font color="blue">establishing</font>  an  MMA-  mandated  <font color="blue">competitive bidding</font> program, or CAP,     physicians who <font color="blue">administer drugs</font> in their offices are offered an option to     acquire injectable and <font color="blue">infused drugs currently covered under</font> the <font color="blue"><font color="blue">Medicare  </font>   </font>Part  B <font color="blue">benefit from vendors</font> who are selected in a <font color="blue">competitive bidding</font>     process</td>
    </tr>
    <tr>
      <td>Winning vendors are selected <font color="blue">based on</font> criteria that include their     bid price</td>
    </tr>
    <tr>
      <td>These new <font color="blue">reimbursement</font> measures, <font color="blue">effective</font> beginning July 1,     2006, <font color="blue">could negatively impact</font> our ability to sell our products</td>
    </tr>
    <tr>
      <td>The MMA also     established a new Part D <font color="blue">prescription</font> drug benefit, which became <font color="blue">effective</font>     January 1, 2006</td>
    </tr>
    <tr>
      <td>Under the <font color="blue">prescription</font> drug benefit, Medicare <font color="blue">beneficiaries</font>     are able to obtain <font color="blue">prescription</font> drug coverage from private sector providers</td>
    </tr>
    <tr>
      <td>These  private  sector  providers are permitted to limit the number of     <font color="blue">prescription</font> drugs that are covered in each <font color="blue">therapeutic</font> category and class     on their <font color="blue">formularies</font></td>
    </tr>
    <tr>
      <td>We <font color="blue"><font color="blue">cannot predict</font> whether</font> our products will be placed     on the <font color="blue">formularies</font> of the private sector <font color="blue">providers participating</font> in the Part     D  program  in  the future, and if our products are not <font color="blue">placed on such</font>     <font color="blue">formularies</font>, this <font color="blue">could negatively impact</font> our ability to sell our products</td>
    </tr>
    <tr>
      <td>It remains <font color="blue">difficult</font> to predict the full impact that the <font color="blue">prescription</font> drug     program,  and the MMA generally, will have on us and our industry</td>
    </tr>
    <tr>
      <td>The     <font color="blue">expanded access</font> to <font color="blue">prescription</font> <font color="blue">medications</font> afforded by Medicare coverage of     <font color="blue">prescription</font> drugs may increase the volume of <font color="blue">pharmaceutical</font> sales</td>
    </tr>
    <tr>
      <td>However,     this <font color="blue">potential sales volume increase may</font> be offset by increased downward     <font color="blue">pricing pressures</font> resulting from the <font color="blue">enhanced purchasing power</font> of private     sector providers who <font color="blue">will negotiate drug pricing on behalf</font> of <font color="blue"><font color="blue">Medicare  </font>   </font><font color="blue">beneficiaries</font> under Part D       There  also  have  been and likely <font color="blue">will continue</font> to be <font color="blue">legislative</font> and     <font color="blue">regulatory</font> proposals at the state and federal levels that <font color="blue">could bring about</font>     <font color="blue">significant</font> changes to the Medicaid <font color="blue">drug rebate program</font> and other federal     <font color="blue">pharmaceutical</font> pricing programs in which we plan to <font color="blue">participate</font> for our     products</td>
    </tr>
    <tr>
      <td>Given  these  and other <font color="blue">recent federal</font> and state <font color="blue">government</font>     <font color="blue">initiatives directed at lowering</font> the total cost of health care, federal and     state <font color="blue">lawmakers will likely continue</font> to <font color="blue">focus on health care reform</font>, the     cost of <font color="blue">prescription</font> <font color="blue"><font color="blue">pharmaceutical</font>s</font> and on the reform of the Medicare and     Medicaid programs</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the <font color="blue">impact on</font> our business of any     <font color="blue">legislation</font> or <font color="blue">regulations</font> that may be adopted in the future</td>
    </tr>
    <tr>
      <td>Any cost     <font color="blue">containment measures</font> and other <font color="blue">healthcare system</font> reforms that are adopted     could have a material adverse effect on our ability to operate profitably</td>
    </tr>
    <tr>
      <td>We may need to change our business practices to <font color="blue">comply with</font> health care         fraud and abuse <font color="blue">regulations</font>, and our failure to <font color="blue">comply with</font> such laws         could <font color="blue">adversely</font> affect our business, <font color="blue">financial condition</font> and results of         <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">operations</font> will be directly, or <font color="blue"><font color="blue">indirectly</font> through</font> our customers,     subject  to various state and <font color="blue">federal fraud</font> and <font color="blue">abuse laws</font>, including,     without <font color="blue">limitation</font>, the federal Anti-Kickback Statute and <font color="blue">False Claims Act</font></td>
    </tr>
    <tr>
      <td>These laws may impact, among other things, our proposed sales, marketing and     <font color="blue">education programs</font></td>
    </tr>
    <tr>
      <td>The federal Anti-Kickback Statute <font color="blue">prohibits persons from knowingly</font> and     willfully  soliciting,  offering, receiving or <font color="blue">providing <font color="blue">remuneration</font></font>,     directly or <font color="blue">indirectly</font>, in exchange for or to <font color="blue">induce either</font> the referral of     an individual, or the furnishing or arranging for a good or service, for     <font color="blue">which payment may</font> be made under a <font color="blue">federal healthcare program such as</font> the     <font color="blue">Medicare  </font>and  <font color="blue">Medicaid  </font>programs</td>
    </tr>
    <tr>
      <td>Several courts have interpreted the     statuteapstas  intent  <font color="blue">requirement</font>  to  mean that if any <font color="blue">one purpose</font> of an     <font color="blue">arrangement</font>  involving  <font color="blue">remuneration</font> is to <font color="blue">induce referrals</font> of federal     healthcare  covered  business,  the  statute  has  been  violated</td>
    </tr>
    <tr>
      <td>The     Anti-Kickback Statute is broad and prohibits many <font color="blue"><font color="blue">arrangement</font>s</font> and practices     that  are  lawful  in  <font color="blue">businesses</font>  outside of the <font color="blue">healthcare industry</font></td>
    </tr>
    <tr>
      <td><font color="blue">Recognizing </font>that the Anti-Kickback Statute is broad and <font color="blue">may technically</font>     prohibit many innocuous or beneficial <font color="blue"><font color="blue">arrangement</font>s</font>, <font color="blue">Congress </font>authorized the     Department of Health and Human Services, Office of Inspector General ( &amp;quote OIG &amp;quote )     to issue a series of <font color="blue">regulations</font>, known as the  &amp;quote <font color="blue">safe harbors</font> &amp;quote</td>
    </tr>
    <tr>
      <td>These safe     <font color="blue">harbors set forth provisions</font> that, if all their applicable <font color="blue"><font color="blue">requirement</font>s</font> are     met, will assure healthcare providers and other parties that they will not     be <font color="blue">prosecuted under</font> the Anti-Kickback Statute</td>
    </tr>
    <tr>
      <td>The failure of a <font color="blue">transaction</font>     or <font color="blue">arrangement</font> to <font color="blue">fit precisely within one</font> or more <font color="blue">safe harbors</font> does not     <font color="blue">necessarily mean</font> that it is illegal or that <font color="blue">prosecution will</font> be pursued</td>
    </tr>
    <tr>
      <td>However, conduct and business <font color="blue"><font color="blue">arrangement</font>s</font> that do not <font color="blue">fully satisfy each</font>     applicable  <font color="blue">safe harbor may</font> result in increased scrutiny by <font color="blue">government</font>     enforcement <font color="blue">authorities</font> such as the <font color="blue">OIG Penalties </font>for violations of the     federal Anti-Kickback Statute include <font color="blue">criminal penalties</font> and <font color="blue">civil sanctions</font>     such as fines, <font color="blue">imprisonment</font> and <font color="blue">possible exclusion from</font> Medicare, <font color="blue">Medicaid  </font>   and other <font color="blue">federal healthcare programs</font></td>
    </tr>
    <tr>
      <td>Many states have <font color="blue">also adopted laws</font>     similar to the federal Anti-Kickback Statute, some of <font color="blue">which apply</font> to the     referral of patients for <font color="blue">healthcare items</font> or <font color="blue">services reimbursed by</font> any     source, not only the <font color="blue">Medicare and Medicaid </font>programs</td>
    </tr>
    <tr>
      <td>The federal <font color="blue"><font color="blue">False Claims Act</font> </font><font color="blue">prohibits persons from knowingly</font> filing or     causing to be filed a false claim to, or the knowing use of <font color="blue">false statements</font>     to obtain <font color="blue">payment from</font>, the federal <font color="blue">government</font></td>
    </tr>
    <tr>
      <td>Suits <font color="blue">filed under</font> the False     Claims Act, known as  &amp;quote qui tam &amp;quote  actions, can be <font color="blue">brought by</font> any individual on     behalf of the <font color="blue">government</font> and such individuals, sometimes known as  &amp;quote relators &amp;quote      or, more commonly, as  &amp;quote whistleblowers &amp;quote , may share in any <font color="blue">amounts paid by</font> the     entity to the <font color="blue">government</font> in fines or settlement</td>
    </tr>
    <tr>
      <td>The frequency of filing of     <font color="blue">qui tam actions</font> has increased <font color="blue">significant</font>ly in <font color="blue">recent years</font>, causing greater     numbers of <font color="blue">healthcare companies</font> to have to defend a <font color="blue">False Claim </font>action</td>
    </tr>
    <tr>
      <td><font color="blue">When     </font>an entity is determined to have violated the federal <font color="blue">False Claims Act</font>, it     may be required to pay up to <font color="blue">three times</font> the <font color="blue">actual damages sustained by</font> the     <font color="blue">government</font>, plus <font color="blue">civil penalties</font> of between dlra5cmam500 to dlra11cmam000 for each     <font color="blue">separate false</font> claim</td>
    </tr>
    <tr>
      <td>Various states have <font color="blue">also enacted laws modeled</font> after     the federal <font color="blue">False Claims Act</font></td>
    </tr>
    <tr>
      <td>In addition to the <font color="blue">laws described</font> above, the Health Insurance Portability     and Accountability Act of 1996 created two new federal crimes: healthcare     fraud and <font color="blue">false statements</font> relating to healthcare matters</td>
    </tr>
    <tr>
      <td>The healthcare     fraud  <font color="blue">statute prohibits knowingly</font> and willfully executing a scheme to     defraud  any  healthcare  <font color="blue">benefit program</font>, including <font color="blue">private payors</font></td>
    </tr>
    <tr>
      <td>A     violation of this statute is a felony and may result in fines, <font color="blue">imprisonment</font>     or  exclusion from <font color="blue">government</font> sponsored programs</td>
    </tr>
    <tr>
      <td>The <font color="blue">false statements</font>     <font color="blue">statute prohibits knowingly</font> and willfully falsifying, concealing or covering     up a material fact or making any <font color="blue">materially</font> false, fictitious or <font color="blue">fraudulent</font>     statement in <font color="blue"><font color="blue">connection</font> with</font> the delivery of or payment for healthcare     benefits, items or services</td>
    </tr>
    <tr>
      <td>A violation of this statute is a felony and may     result in fines or <font color="blue">imprisonment</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">operations</font> are found to be in violation of any of the <font color="blue">laws described</font>     above and other applicable state and <font color="blue">federal fraud</font> and <font color="blue">abuse laws</font>, we may be     subject to penalties, including civil and <font color="blue">criminal penalties</font>, damages,     fines, exclusion from <font color="blue">government</font> healthcare programs, and the <font color="blue">curtailment</font> or     <font color="blue">restructuring</font> of our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our business <font color="blue">exposes us</font> to <font color="blue">product liability</font> claims</td>
    </tr>
    <tr>
      <td>The testing, <font color="blue">manufacture</font>, marketing and sale of our <font color="blue">products involve</font> an     <font color="blue">inherent risk</font> that <font color="blue">product liability</font> claims will be asserted <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>We     face the risk that the use of our products in human <font color="blue">clinical trials</font> will     result in <font color="blue">adverse effects</font></td>
    </tr>
    <tr>
      <td>If we complete <font color="blue">clinical testing</font> for our products     and receive <font color="blue">regulatory</font> approval to market our products, we will mark our     <font color="blue">products with warnings</font> that identify the known potential <font color="blue">adverse effects</font> and     the patients who should not receive our product</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot ensure</font> that     physicians  and patients will <font color="blue">comply with</font> these warnings</td>
    </tr>
    <tr>
      <td>In addition,     unexpected <font color="blue">adverse effects</font> may occur <font color="blue">even with use</font> of our products that     receive approval for <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>Although we are insured against such     risks in <font color="blue"><font color="blue">connection</font> with</font> <font color="blue">clinical trials</font>, our present <font color="blue">product liability</font>     <font color="blue">insurance may</font> be inadequate</td>
    </tr>
    <tr>
      <td>A successful <font color="blue">product liability</font> claim in excess     of  our <font color="blue">insurance coverage could</font> have a material adverse effect on our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Any successful     <font color="blue">product liability</font> claim <font color="blue">may prevent us from</font> obtaining <font color="blue">adequate product</font>     <font color="blue">liability insurance</font> in the <font color="blue">future on commercially desirable</font> or reasonable     terms</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">product liability</font> coverage may cease to be available in     sufficient  amounts  or  at an acceptable cost</td>
    </tr>
    <tr>
      <td>An <font color="blue">inability</font> to obtain     <font color="blue">sufficient insurance coverage at</font> an acceptable cost or otherwise to protect     against <font color="blue">potential product</font> liability claims <font color="blue">could prevent</font> or inhibit the     <font color="blue">commercialization</font> of our <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>A <font color="blue">product liability</font> claim     or <font color="blue">recall would</font> have a material adverse effect on our reputation, business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our business <font color="blue">involves environmental risks</font></td>
    </tr>
    <tr>
      <td>In  <font color="blue">connection</font>  with  our  research and <font color="blue">development</font> <font color="blue">activities</font> and our     <font color="blue">manufacture</font> of materials and products, we are subject to federal, state and     local laws, rules, <font color="blue">regulations</font> and <font color="blue">policies governing</font> the use, generation,     <font color="blue">manufacture</font>,  storage,  air emission, effluent discharge, handling and     disposal of certain materials, biological specimens and wastes</td>
    </tr>
    <tr>
      <td>Although we     believe that we have <font color="blue">complied with</font> the applicable laws, <font color="blue">regulations</font> and     policies in all material respects and have not been required to correct any     material <font color="blue">noncompliance</font>, we may be required to incur <font color="blue">significant</font> costs to     <font color="blue">comply with</font> environmental and health and safety <font color="blue">regulations</font> in the future</td>
    </tr>
    <tr>
      <td>Our  research and <font color="blue">development</font> involves the <font color="blue">controlled use</font> of <font color="blue">hazardous</font>     materials, including but not limited to certain <font color="blue">hazardous</font> chemicals and     <font color="blue">radioactive materials</font></td>
    </tr>
    <tr>
      <td>Although we believe that our <font color="blue">safety procedures</font> for     handling  and  disposing  of  such materials <font color="blue">comply with</font> the standards     <font color="blue">prescribed by</font> state and federal <font color="blue">regulations</font>, we <font color="blue">cannot completely eliminate</font>     the risk of <font color="blue">contamination</font> or <font color="blue">injury from</font> these materials</td>
    </tr>
    <tr>
      <td>In the event of     such an occurrence, we could be held liable for any damages that result and     any <font color="blue">such liability could exceed</font> our resources</td>
    </tr>
  </tbody>
</table>